Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users

AIDS

Volumn 13, Issue 8, 1999, Pages 981-985

  Alexander, Christopher S ^a   Dong, Winnie ^a   Schechter, Martin T ^a,b   O'Shaughnessy, Michael V ^a,c   Strathdee, Steffanie A ^a   Mo, Theresa ^a   Montaner, Julio S G ^a,c   Harrigan, P Richard ^a,d  

^a ST PAUL S HOSPITAL   (Canada)

^b Department of Health Care ^*  (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

Antiretrovirals; HIV; Injecting drug use; Resistance

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE; RNA DIRECTED DNA POLYMERASE; VIRUS ENZYME; VIRUS RNA;

ARTICLE; CANADA; DRUG RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEROCONVERSION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; BASE SEQUENCE; CANADA; DISEASE OUTBREAKS; DNA, VIRAL; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL LOAD;

EID: 0032967709     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199905280-00015     Document Type: Article

References (39)

1. Larder BA. Viral resistance and the selection of antiretroviral combinations. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 10 (suppl 1):S28-S33.
2. Kuritzkes DR. Clinical significance of drug resistance in HIV-1 infection. AIDS 1996, 10 (suppl 5): S27-S31.
3. Moyle GJ. Current knowledge of HIV-1 reverse transcriptase mutations selected during nucleoside analogue therapy: the potential to use resistance data to guide clinical decisions. J Antimicrob Chemother 1997, 40:765-777.
4. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society - USA Panel. JAMA 1998, 279:1984-1991.
5. Feinberg J, Petropoulos CJ, Hellmann D, Richman DD. Heterosexual Transmission of NNRTI-Resistant HIV-1. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, February 1999 [abstract 219].
6. S. Wegner, Mascola J, Barile A, et al. High frequency of antiretroviral drug resistance in HIV-1 from recently infected therapy naive individuals. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, February 1999 [abstract LB9].
7. Keiser R, D'aquila E, Connick N et al. The spectrum and frequency of reduced antiretroviral drug susceptibility with primary HIV infection in the United States. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, February 1999 [abstract LB10].
8. Wainberg M, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998, 279: 1977-1983.
9. Erice A, Mayers DL, Strike DG, et al. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med 1993, 328:1163-1165.
10. Conway B, Montessori V, Rouleau D, et al. Primary lamivudine resistance in acute HIV infection. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. St. Petersburg, June 1997 [abstract 103].
11. Masuhr A, Arateh K, Simon V, McKlinghoff C, Moll A. Detection of genotypic drug resistance to antiviral nucleoside inhibitors in short-time pretreated and drug-naive HIV-1 infected patients as predictor of treatment failure in high acting retroviral therapy (HAART). 12th World AIDS Conference. Geneva, June 1998 [abstract 32282].
12. Imrie A, Beveridge A, Genn W, Vizzard J, Cooper DA. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. J Infect Dis 1997, 175: 1502-1506.
13. Fontaine E, Hemmer R, Fontaine E, et al. Drug resistance mutations in HIV-1 strains from treatment-naive patients. 12th World AIDS Conference. Geneva, June 1998 [abstract 42199].
14. de Ronde A, Schuurman R, Goudsmit J, van den Hoek A, Boucher C. First case of new infection with zidovudine-resistant HIV-1 among prospectively studied intravenous drug users and homosexual men in Amsterdam, The Netherlands [letter]. AIDS 1996, 10:231-232.
15. Conlon CP, Klenerman P, Edwards A, Larder BA, Phillips RE. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. J Infect Dis 1994, 169:411-415.
16. Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998, 339:307-311.
17. Yerly S, Schockmel G, Bru JP, Herchel B, Perrin L. Frequency of transmission of drug-resistant variants in individuals with primary HIV-1 infection. 12th World AIDS Conference. Geneva, June 1998 [abstract 228:32280].
18. Braun P, Knechten H, Hirzmann I, Ruback C. Detection of mutations in the HIV-1 reverse transcriptase (RT) gene and its predictive value at the start of antiretroviral therapy. 12th World AIDS Conference. Geneva, June 1998 [abstract 32311].
19. Friedman SR, Des Jarlais DC. HIV among drug injectors: the epidemic and the response. AIDS Care 1991, 3:239-250.
20. Des Jarlais DC, Friedman SR, Choopanya K, Vanichseni S, Ward TP. International epidemiology of HIV and AIDS among injecting drug users. AIDS 1992, 6:1053-1068.
21. Robertson JR, Bucknall AB, Welsby PD, et al. An epidemic of AIDS-related virus (HTLV-III/LAV) infection among intravenous drug abusers in a Scottish general practice. BMJ 1986, 292; 527-530.
22. Stimson GV. Reconstruction of sub-regional diffusion of HIV infection among injecting drug users in South-East Asia: implications for early intervention [letter]. AIDS 1994, 8:1630-1632.
23. Weniger BG, Limpakarnjanarat K, Ungchusak K, et al. The epidemiology of HIV infection and AIDS in Thailand. AIDS 1991, 5(suppl 2):S71-S85.
24. European Centre for the Epidemiological Monitoring of AIDS. HIV/AIDS Surveillance in Europe, 1994-1996. Paris: European Centre for the Epidemiological Monitoring of AIDS; 1996.
25. Hamers FF, Batter V, Downs AM, Alix J, Cazein F, Brunet JB. The HIV epidemic associated with injecting drug use in Europe: geographic and time trends. AIDS 1997, 11:1365-1374.
26. Centers for Disease Control. Update: trends in AIDS incidence, deaths, and prevalence - United States, 1996. MMWR 1997, 46:65-173.
27. Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Pub Health 1996, 86:643-654.
28. Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS 1997, 11:F59-F65.
29. Harrigan PR, Kinghorn I, Bloor S, et al. Significance of amino acid variation at human immunodeficiency virus type-1 reverse transcriptase residue 210 for zidovudine susceptibility. J Virol 1996, 70:5930-5934.
30. Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M, Henfrey RD. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 1993, 365:671-673.
31. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989, 246:1155-1158.
32. Kellam P, Boucher CA, Larder BA. Fifth mutation in human immunodeficiency virus type-1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 1992, 89:1934-1938.
33. Mayers DL, Yerly S, Perrin L, et al. Prevalence and clinical course of persons seroconverting with AZT-resistant (AZTR) HIV-1 in Switzerland, Australia and the United States between 1988 and 1994. AIDS Res Hum Retroviruses 1995, 11(suppl 1):S162.
34. Rubio A, Leal M, Pineda JA, et al. Increase in the frequency of mutation at codon 215 associated with zidovudine resistance in HIV-1-infected antiviral-naive patients from 1989 to 1996 [letter]. AIDS 1997, 11:1184-1186.
35. Goudsmit J, de Ronde A, Ho DD, Perelson AS. Human immonodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase. J Virol 1996, 70:5662-5663.
36. Strathdee SA, Palepu A, Cornelisse PGA, et al. Barriers to utilization of free antiretroviral therapies in injection drug users with HIV infection. JAMA 1998, 208:547-549.
37. Celentano DD, Valhov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA 1998, 280:544-546.
38. Bangsberg D, Tulsky JP, Hecht RM, Moss AR. Protease inhibitors in the homeless. JAMA 1997, 278:1962-1969.
39. Jacquez JA, Koopman JS, Simon CP, Longini IM. The role of primary infection in epidemics of HIV infection in gay cohorts. J Acquir Immune Defic Syndr 1994, 7:1169-1184.